Trial results for adalimumab (Humira, Hulio, Yusimry, Yuflyma, Idacio, Simlandi, Amjevita, Cyltezo, Hadlima, Hyrimoz) in pediatric patients with juvenile psoriatic arthritis (JPsA) and enthesitis-related arthritis (ERA) were posted on ClinicalTrials.gov on 2025-06-05. The study compared adalimumab to ixekizumab, with adalimumab demonstrating a 95.0% JIA ACR 30 response rate compared to 88.9% for ixekizumab in the open-label treatment (OLT) period.
Background
Juvenile idiopathic arthritis (JIA) encompasses several categories, including enthesitis-related arthritis (ERA) and juvenile psoriatic arthritis (JPsA). These conditions affect children and adolescents, causing joint inflammation, pain, and potentially long-term disability. Effective treatments are crucial for managing symptoms and improving quality of life in this pediatric population.
Trial design
This Phase 3 study (NCT04527380) enrolled 101 participants to evaluate the safety and efficacy of ixekizumab in children with Juvenile Psoriatic Arthritis and Enthesitis Related Arthritis. The trial included a comparison arm with adalimumab, aiming to assess the study drug ixekizumab against an established treatment for these conditions.
Key results
Key measurements from the open-label treatment (OLT) period showed the following:
- For Juvenile Idiopathic Arthritis (JIA) American College of Rheumatology (ACR) 30 response, 95.0% of participants in the Adalimumab - OLT Period group achieved this outcome, compared to 88.9% in the Ixekizumab - OLT Period group.
- For JIA ACR 50 response, 90.0% of participants in the Adalimumab - OLT Period group achieved this, versus 79% in the Ixekizumab - OLT Period group.
- For JIA ACR 70 response, 65.0% of participants in the Adalimumab - OLT Period group achieved this, versus 64.2% in the Ixekizumab - OLT Period group.
- For JIA ACR 90 response, 40.0% of participants in the Adalimumab - OLT Period group achieved this, versus 29.6% in the Ixekizumab - OLT Period group.
- For JIA ACR 100 response, 35.0% of participants in the Adalimumab - OLT Period group achieved this, versus 18.5% in the Ixekizumab - OLT Period group.
- Regarding the change from baseline in Psoriasis Area and Severity Index (PASI) for JPsA participants with at least 3% Body Surface Area (BSA) at baseline, the Ixekizumab - OLT Period group showed a mean change of -3.80 (Standard Deviation: 3.541), while the Adalimumab - OLT Period group showed a mean change of -0.70.
What this means
The results indicate that adalimumab generally showed higher percentages of JIA ACR 30, 50, 70, 90, and 100 responses compared to ixekizumab in the open-label treatment period for pediatric patients with juvenile psoriatic arthritis and enthesitis-related arthritis. Conversely, ixekizumab demonstrated a greater mean reduction in PASI score for juvenile psoriatic arthritis patients. These comparative findings provide clinicians with data on the efficacy profiles of both treatments in specific aspects of these complex pediatric rheumatic conditions.
Source
The information regarding these trial results was obtained from ClinicalTrials.gov, a public database of clinical studies. The results for study NCT04527380, titled "A Study of Ixekizumab (LY2439821) in Children With Juvenile Idiopathic Arthritis Categories of Enthesitis-related Arthritis (Including Juvenile Onset Ankylosing Spondylitis) and Juvenile Psoriatic Arthritis," were posted on 2025-06-05 on clinicaltrials.gov.